Immunai Funding & Investors
Immunai is a biotech company that combines single-cell genomics with ML algorithms to enable high-resolution profiling of the immune system. Immunai's mission is to map the entire immune system and its functions using single-cell genomics and machine learning. Immunai leverages single-cell technologies to profile cells from a blood sample, and uses machine-learning algorithms (powered by its proprietary database) to map the hundreds of cell types and their states to create an immune profile. They work on biomarker discovery and insights that identify how a cell responds to its changing environment. The company is located in New York City, San Francisco, and Tel Aviv, Israel.
immunai.comTotal Amount Raised: $295,000,000
Immunai Funding Rounds
Series B
$215,000,000
Series B Investors
Koch Disruptive TechnologiesTalos VC8VCAlexandria Venture InvestmentsPiedmont Capital InvestmentsMeron CapitalIConSeries B
$215,000,000
Series B Investors
Koch Disruptive TechnologiesTalos VC8VCAlexandria Venture InvestmentsPiedmont Capital InvestmentsMeron CapitalIConSeries A
$60,000,000
Series A Investors
Catalio Capital ManagementCharles and Lynn Schusterman Family PhilanthropiesDexcel PharmaDuquesne Family OfficeTLV PartnersViola GroupMeron CapitalSeed
$20,000,000
Seed Investors
TLV PartnersViola GroupMeron CapitalGefen CapitalSeries A
$60,000,000
Series A Investors
Catalio Capital ManagementCharles and Lynn Schusterman Family PhilanthropiesDexcel PharmaDuquesne Family OfficeTLV PartnersViola GroupMeron CapitalSeed
$20,000,000
Seed Investors
TLV PartnersViola GroupMeron CapitalGefen Capital